Acadia Pharmaceuticals Inc’s recently made public that its EVP, COO, HEAD OF COMMERCIAL Teehan Brendan unloaded Company’s shares for reported $0.17 million on Nov 19 ’24. In the deal valued at $16.81 per share,10,329 shares were sold. As a result of this transaction, Teehan Brendan now holds 62,105 shares worth roughly $ 1.23 million.
Then, Kihara James sold 4,073 shares, generating $68,467 in total proceeds. Upon selling the shares at $16.81, the PRINCIPAL ACCOUNTING OFFICER now owns 19,863 shares.
Before that, Schneyer Mark C. sold 10,259 shares. Acadia Pharmaceuticals Inc shares valued at $172,454 were divested by the EVP, CHIEF FINANCIAL OFFICER at a price of $16.81 per share. As a result of the transaction, Schneyer Mark C. now holds 53,302 shares, worth roughly $1.05 million.
Deutsche Bank initiated its Acadia Pharmaceuticals Inc [ACAD] rating to a Hold in a research note published on February 11, 2025; the price target was $22. A number of analysts have revised their coverage, including Guggenheim’s analysts, who decreased its forecast for the stock in early January from “a Buy” to “a Neutral”. Morgan Stanley revised its rating on August 07, 2024. It rated ACAD as “an Equal-weight” which previously was an “an Overweight”.
Price Performance Review of ACAD
On Tuesday, Acadia Pharmaceuticals Inc [NASDAQ:ACAD] saw its stock fall -1.50% to $19.74. Over the last five days, the stock has gained 4.56%. Acadia Pharmaceuticals Inc shares have risen nearly 7.57% since the year began. Nevertheless, the stocks have fallen -22.77% over the past one year. While a 52-week high of $26.56 was reached on 02/18/25, a 52-week low of $14.15 was recorded on 01/14/25. SMA at 50 days reached $18.01, while 200 days put it at $16.53.
Levels Of Support And Resistance For ACAD Stock
The 24-hour chart illustrates a support level at 19.41, which if violated will result in even more drops to 19.08. On the upside, there is a resistance level at 20.18. A further resistance level may holdings at 20.62. The Relative Strength Index (RSI) on the 14-day chart is 60.52, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.83, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 24.34%. Stochastics %K at 86.55% indicates the stock is a selling.
The most recent change occurred on June 27, 2024 when BMO Capital Markets began covering the stock and recommended ‘”an Outperform”‘ rating along with a $31 price target.
